BBI-3000, a completely novel potent topical/oral rexinoid, is currently in the pre-clinical stage of development for the treatment of acne.  

In preclinical studies performed by Brickell, BBI-3000 displayed activity that differentiated it from the leading topical retinoids currently available on the market. In medical dermatology, topical retinoids are typically indicated for treatment of acne and/or psoriasis and are available on the market as monotherapy or combination therapy.

In June 2014, Brickell entered into a license agreement with Merz, whereby Merz has assumed the full cost and responsibility for future development and commercialization of the BBI-3000, initially for North America.